To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr Valves (TRANSFORM)

Pulmonx

Status

Completed

Conditions

Heterogeneous Emphysema

COPD

Treatments

Device: ELVR (Endoscopic Lung Volume Reduction) with Zephyr Valves

Study type

Interventional

Funder types

Industry

Identifiers

NCT02022683

630-0015/A

Details and patient eligibility

About

To compare the clinical outcomes of Endoscopic Lung Volume Reduction (ELVR) using Pulmonx Zephyr Valves vs. Standard of Care (SoC) in the treatment of heterogeneous emphysema subjects in a controlled trial design setting.

Enrollment

97 patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Obtained informed consent.
Diagnosis of heterogeneous emphysema with a heterogeneity index of ≥10 % between target and adjacent lobes.
Subjects of both genders of at least 40 years of age.
15 % predicted ≤ FEV1≤ 45% predicted.
TLC > 100% and RV ≥ 180% predicted.
150 meters < 6MWD < 450 meters.
Non-smoker >8 weeks prior to signing the Informed Consent.
CV negative target lobe.

Additional inclusion criterion French CIP*:

If treated in France, Subject must be entitled to French social security

Exclusion criteria

Any contraindication for bronchoscopic procedure.
Evidence of active pulmonary infection.
History of 2 or more exacerbations requiring hospitalization over the past 12 months.
Known pulmonary hypertension that according to the physician will be unsuitable for EBV treatment.
Myocardial infarction or other relevant cardiovascular events in the past 6 months.
Significant bronchiectasis seen at CT scan.
Greater than two tablespoons of sputum production per day.
Prior LVR or LVRS procedure. Criterion 8 French CIP wording*: Prior lung transplant, median sternotomy, LVR or LVRS procedure (including lobectomy).
Pulmonary nodule requiring follow-up within any lobe.
Pregnant or nursing women. French CIP wording*: Subject is pregnant or lactating, or plans to become pregnant within the study timeframe.
Hypercapnia (paCO2 > 7.33 kPa).
Current diagnosis of asthma.
> 25mg Prednisolon (or equivalent) use/days.
Any other condition that as judged by the investigator may make follow-up or investigations inappropriate.
Evidence of pleural adhesions or earlier pulmonary surgery.
Severe Bullous Emphysema (> 1/3 Hemithorax)
Any subject that according to the Declaration of Helsinki is unsuitable for enrollment.

Additional exclusion criteria in the French CIP*:

History of allergy to silicone and/or nitinol.
If treated in France, Subject is a "personne vulnerable" as defined by French regulation.
Simultaneous participation in another drug and/or medical device related clinical.